Skip to content

Startup & venture capital news

Soufflé Therapeutics raises USD 135 million for targeted RNA medicines

Juvia Group leads the Boston biotechnology company's Series B.

By /

LinkedInX
Soufflé Therapeutics: Soufflé Therapeutics raises USD 135 million for targeted RNA medicines
Soufflé Therapeutics official website; photographer not stated. Licence: Not stated.

Boston biotechnology company Soufflé Therapeutics announced a USD 135 million Series B on 13 October 2026, led by Juvia Group. The new financing follows its earlier USD 200 million Series A and should not be confused with that previous round. Led by CEO Amir Nashat, the company is developing technology intended to deliver RNA medicines to selected cell types beyond conventional delivery targets. Its REMEDY platform supports programmes addressing muscle and cardiovascular conditions. The funding will advance research and clinical development. Founder links include Robert Langer and Susan Langer. Therapeutic effectiveness and clinical outcomes remain matters for future evidence.

Keep reading

More Funding

All stories